Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism

Current Opinion in Lipidology

Volumn 10, Issue 3, 1999, Pages 237-244

  Packard, Chris J ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CELL SURFACE RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR RISK; DISORDERS OF LIPOPROTEIN METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEINS B; CORONARY DISEASE; HUMANS; LIPOPROTEINS, LDL; RISK FACTORS; TRIGLYCERIDES;

EID: 0032838304     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199906000-00006     Document Type: Review

References (74)

1. 1 Goldstein JL, Brown MS. The low density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1977; 46:897-930.
2. 2 Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Curr J Biochem 1977; 77:31-36.
3. 3 Shepherd J, Cobbe SM, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
4. 4 The Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
5. 5 Brown MS, Goldstein JL. Heart attacks: gone with the century. Science. 1996; 272:629.
6. 6 West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445.
7. 7 Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97:1446-1452.
8. 8 Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 1992; 152:28-34.
9. 9 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.
10. 10 Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, et al. Postprandial lipemia, fenotibrate and coronary artery disease. Atherosclerosis 1990; 85:193-202.
11. 11 Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992; 12:1336-1345.
12. 12 Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17:3542-3556.
13. 13 Walsh BW, Schiff I, Rosner B, Breenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196-1204.
14. 14 Malmström R, Packard CJ, Watson TDG, Rannikko S, Caslake M, Bedford D, et al. Metabolic basis of hypotriglyceridemic effect of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17,7:1454-1464.
15. 15 Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993; 91:748-758.
16. 16 Björkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res 1998; 39:1412-1420.
17. 17 Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteinB-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A 1993; 90:2069-2073.
18. 18 Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34:2033-2040.
19. 19 Björkegren J, Packard CJ, Hamsten A, Bedford D, Caslake MJ, Forster L, et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996; 37:76-86.
20. 20 Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 1998; 105:585-625.
21. 21 Cryer DR, Matsushima T, Marsh JB, Yudkoff M, Coates PM, Cortner JA. Direct measurement of apolipoprotein B synthesis in human very low density lipoprotein using stable isotopes and mass spectrometry. J Lipid Res 1986; 27:508-516.
22. 22 Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer E. Measurement of very low density and low density lipoprotein apolipoprotein B-100 and high density lipoprotein apoA-I production in human subjects using deuterated leucine. J Clin Invest 1990; 85:804-811.
23. 23 Lewis GF, Uffelman KD, Szelo LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95:158-166.
24. 24 Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994; 5:236-240.
25. 25 Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997; 8:146-153.
26. 26 Pease RJ, Leiper JM. Regulation of hepatic apolipoprotein-containing lipoprotein secretion. Curr Opin Lipidol 1996; 7:132-138.
27. 27 Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B assembly. Curr Opin Lipidol 1997; 8:131-137.
28. 28 Wetterau JR, Aggerbeck LP, Bouma M-E, Eisenberg C, Munck A, Hermier M et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258:999-1001.
29. 29 Thompson GM, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37:439-447.
30. 30 Schumaker VN, Phillips ML, Chatterton JE. Apolipoprotein B and low density lipoprotein structure: implications for the biosynthesis of triglyceride-rich lipoproteins. Adv Prot Chem 1994; 45:203-247.
31. 31 Borén J, Rustaeus S, Olofsson S-O. Studies on the assembly of apolipoprotein B-100 and B-48-containing very low density lipoprotein in McArdle RH-7777 cells. J Biol Chem 1994; 269:25879-25888.
32. 32 Thrift RN, Forte TM, Cahoon BE, Shore VG. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. J Lipid Res 1986; 27:236-250.
33. 33 Borén J, Vencant MM, Young SG. ApoB-100 containing lipoproteins are secreted by the heart. J Clin Invest 1998; 101:1197-1202.
34. 34 Soutar AK, Myant NB, Thompson GR. Simultaneous measurement of apolipoprotein B turnovers in very low and low density lipoproteins in familial hypercholesterolemia. Atherosclerosis 1977; 28:247-256.
35. 35 Shames DM, Havel RJ. De novo production of low density lipoproteins: fact or fancy. J Lipid Res 1991; 32:1099-1112.
36. 36 Alexander CA, Hamilton RL, Havel RJ. Subcellular localization of B apoprotein of plasma lipoprotein in rat liver. J Cell Biol 1976; 69:241-263.
37. 37 Gordon DA, Jamil H, Gregg RE, Olofsson S-O, Borén J. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem 1996; 271:33047-33053.
38. 38 Huff MW, Burnett JR. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 1997; 8:138-145.
39. 39 Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-1921.
40. 40 Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992; 3:377-383.
41. 41 Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
42. 42 Swinkels DW, Demacker PNM, Hendriks JCM, van't Laar A. Low density lipoprotein subfractions and relationships to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 1989; 9:604-613.
43. 43 Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241-253.
44. 44 Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992; 12:187-195.
45. 45 McNamara JR, Campos H, Ordovas JM, Paterson J, Wilson PWF, Schaefer EJ. Effect of gender, age and lipid status on low density lipoprotein subfraction distribution. Arteriosclerosis 1987; 7:483-490.
46. 46 Tan CE, Forster L, Caslake MJ, Bedford D, Watson TDG, McConnell M, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfractions in normolipemic men and women. Arterioscler Thromb Vasc Biol 1995; 15:1839-1848.
47. 47 Sattar N, Greer IA, Loudon J, Lindsay G, McConnell M, Shepherd J, Packard CJ, Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. J Clin Endocrinol Metab 1997; 82:2483-2491.
48. 48 Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA, Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis 1993; 98:33-49.
49. 49 Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993; 13:147-153.
50. 50 Watson TDG, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J. Determinants of low-density lipoprotein subfraction distribution and concentrations in young normolipidemic subjects. Arteriosclerosis 1994; 14:902-910.
51. 51 Lipid Research Clinics Population Studies Data Book. US Department of Health and Human Services. National Institutes of Health Publication No. 80-1527. 1980.
52. 52 Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16:763-772.
53. 53 Sakai N, Matsuzawa Y, Hirano K, Yamashita S, Nozaki S, Ueyama Y, et al. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb 1991; 11:71-79.
54. 54 Hirano K, Matsuzawa Y, Sakai N, Hireoka H, Nozaki S, Funahashi T et al. Polydispersed low density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction in cholesteryl ester transfer protein activity. Metabolism 1992; 41:1313-1318.
55. 55 Superko HR, Krauss RM. Different effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992; 95:69-76.
56. 56 Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108:137-148.
57. 57 Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849-853.
58. 58 Frick MH, Syvanne M, Nieminen MS, Kauma H, Mayaholme S, Vintanen V et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in man with low levels of HDL cholesterol. Lopid Angiography Trial (LOCAT). Circulation 1997; 96:2137-2143.
59. 59 Gofrnan JW, Delalla O, Glazier F, Freeman NK, Lindgren FT, Nichols AV et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary artery disease. Plasma 1954; 2:413.
60. 60 Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995; 6:209-214.
61. 61 Zambon A, Hokanson JE. Lipoprotein classes and coronary disease regression. Curr Opin Lipidol 1998; 9:329-336.
62. 62 Syvanne M, Niemoinen MS, Frick MH, Kauma H, Mayaholme S, Vintanen V. Associations between lipoproteins and the progression of coronary and vein graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998; 98:1993-1999.
63. 63 Campos E, Jäckle S, Chen GC, Havel RJ. Isolation and characterisation of two distinct species of human very low density lipoproteins lacking apolipoprotein E. J Lipid Res 1996; 37:1897-1906.
64. 64 Devanaj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med 1998; 104:445-450.
65. 65 Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
66. 66 Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor. Arterioscler Thromb Vasc Biol 1997; 17:149-155.
67. 67 Camejo G. Hurt-Camejo E, Wiklund O. Bondjers G. Association of apoB lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139:205-222.
68. 68 Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996; 124:261-271.
69. 69 Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan binding site in LDL. A single point mutation severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101:2658-2664.
70. 70 Grundy SM. Cholesterol and coronary heart disease: a new era. JAMA 1986; 256:2849-2858.
71. 71 Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Arteriosclerosis 1981; 1:13-24.
72. 72 Caslake MJ, Packard CJ, Series JJ, Yip B, Dagen MM, Shepherd J. Plasma triglyceride and low density lipoprotein metabolism. Eur J Clin Invest 1992; 22:96-104.
73. 73 Suporko HR. What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials. Curr Opin Lipidol 1996; 7:363-368.
74. 74 Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cop M, Connolly F et al. An MTP inhibitor that normalises atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282:751-754.